AZ-11713908

AZ-11713908 is an experimental benzimidazole cannabinoid ligand developed by AstraZeneca as part of research into peripherally acting cannabinoid receptor agonists. It is structurally distinct from the indole- and indazole-based synthetic cannabinoids commonly found in illicit herbal products. Published medicinal-chemistry literature describes it as a potent CB₁ agonist and a partial CB₂ agonist, with limited penetration into the brain.

Chemistry and research background

AZ-11713908 is a benzimidazole derivative containing a cyclohexylmethyl substituent, an ethoxypyridylmethyl group and a thiophene sulfonamide. The FDA Substance Registration System records its chemical identity and molecular formula, while noting that database registration does not imply regulatory approval (FDA Substance Registration System: AZ-11713908).

The compound emerged from pharmaceutical research rather than from the recreational synthetic cannabinoid market. It is often grouped with synthetic cannabinoids because of its activity at cannabinoid receptors, but its development context and intended pharmacology are different from those of many substances sold as Spice or K2.

Pharmacology

A review of cannabinoid medicinal chemistry describes AZ-11713908 as a potent CB₁ agonist and a partial agonist at CB₂. The compound showed poor blood–brain barrier penetration and was therefore investigated as a peripherally selective ligand. Preclinical studies reported analgesic effects in inflammatory and neuropathic pain models (Aghazadeh Tabrizi and colleagues, 2016).

Its peripheral profile was intended to retain potential analgesic activity while limiting the central effects associated with CB₁ receptor activation. This was a preclinical research strategy, not evidence of an approved or clinically established treatment.

Effects in experimental models

The published review summarises analgesic activity in animal models of inflammatory and neuropathic pain. There is no substantial human clinical literature establishing a subjective or recreational effect profile for AZ-11713908.

Because its distribution into the brain was reported to be limited, it should not automatically be described as producing the same central psychoactive effects as potent recreational CB₁ agonists.

Toxicity and research limitations

No established human safety profile, clinical efficacy trial or pharmacokinetic study was identified in the sources reviewed here. Its acute toxicity, metabolism, dependence potential and long-term effects in people remain uncertain.

AZ-11713908 is best understood as an experimental cannabinoid receptor ligand. Its inclusion in broad lists of synthetic cannabinoids shows neither widespread recreational use nor risks equivalent to those of illicit high-efficacy CB₁ agonists.

Related compounds

AZ-11713908 is related by research context to AZD-1940 and other benzimidazole cannabinoid ligands. Both compounds were investigated for peripheral cannabinoid-receptor activity, but their structures and pharmacological profiles are distinct.